Irbesartan/Hct Al

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hct Al, is an angiotensin II receptor blocker (ARB) and thiazide diuretic presented as an oral tablet for oral use. It lowers elevated blood pressure and is prescribed for adults with hypertension.

GNH USA supplies Irbesartan/Hct Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hct Al is used to manage high blood pressure within the antihypertensive drug class.

- Essential hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient. - Secondary hypertension: assists in controlling blood pressure caused by identifiable underlying conditions. - Hypertension with fluid retention: combines vasodilation and diuresis to improve overall pressure control.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury - Hyperuricemia or gout flare - Angioedema - Hepatic dysfunction - Severe hypotension

Before initiating therapy, consider the following precautions.

- Pregnancy: Category D – avoid use unless clearly needed. - Renal impairment: monitor kidney function and adjust dose if required. - Hepatic disease: use with caution; monitor liver enzymes. - Electrolyte balance: check serum potassium and sodium regularly. - Concomitant diuretics: assess risk of excessive diuresis. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Irbesartan/Hct Al may interact with several medicines; categorize the risk level.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: increased lithium levels, potential toxicity. - NSAIDs: may reduce antihypertensive efficacy and affect renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood‑pressure effect, monitor for hypotension. - Antidiabetic agents: may enhance hypoglycemic response. - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan concentrations.